Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Core and Main Inc (CNM) vs GeneDx Holdings Corp (WGS) Price & Performance

Core and Main IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Core and Main Inc vs GeneDx Holdings Corp — how do they compare? Core and Main Inc trades at $46.18 (market cap $8.62B), while GeneDx Holdings Corp trades at $82.2 (market cap $2.45B). The key difference: Core and Main Inc is far larger — about 3.5× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Core and Main Inc nearer its low. Which is the better fit depends on your goals.

CNMWGS
Market Cap
$8.62B$2.45B
Sector
TechnologyTechnology
52-Week High
$66.98$167.51
52-Week Low
$42.37$34.51
Enterprise Value
$10.92B$2.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Core and Main Inc

Core & Main (CNM) trades at $46.06, down 0.52% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.57 exceeding expectations. Financials show solid profitability with a 5.87% net income margin and 23.73% ROE, though debt levels remain elevated. Recent news includes institutional position adjustments and a $750 million senior notes offering priced in June 2026.

Outlook is cautiously optimistic with analyst consensus favoring Buy ratings (57%). Key opportunities include margin expansion and municipal strength, while risks involve high debt, competitive pressures, and reliance on infrastructure spending. The stock's valuation at a P/E of 19.76 appears reasonable given growth prospects, but investors should monitor execution against FY26 revenue guidance of $7.8–7.9 billion.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.

Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Core and Main Inc

Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.

Read more on CNM

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS